Effect of neoadjuvant chemoradiotherapy on p53 and SOX2 protein expression in esophageal adenocarcinoma

被引：2
|
作者：
Suzuki, Lucia [1 ]
Nieboer, Daan [2 ]
van Lanschot, Jan J. B. [3 ]
Spaander, Manon C. W. [4 ]
Looijenga, Leendert H. J. [1 ,5 ]
Biermann, Katharina [1 ,6 ]
机构：
[1] Erasmus MC Univ Med Ctr Rotterdam, Dept Pathol, Rotterdam, Netherlands
[2] Erasmus MC Univ Med Ctr Rotterdam, Dept Publ Hlth, Rotterdam, Netherlands
[3] Erasmus MC Univ Med Ctr Rotterdam, Dept Surg, Rotterdam, Netherlands
[4] Erasmus MC Univ Med Ctr Rotterdam, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands
[5] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands
[6] MVZ Histol Zytol & Mol Diagnost Duren GmbH, Dept Pathol, Inst Pathol, Duren, Germany
来源：
BIOMARKERS IN MEDICINE | 2020年 / 14卷 / 09期
关键词：
biomarkers; esophageal adenocarcinoma; esophageal neoplasms; neoadjuvant therapy SOX2 protein; tumor suppressor protein p53; ADJUVANT CHEMOTHERAPY; PREOPERATIVE CHEMORADIOTHERAPY; CHEMORADIATION; SURVIVAL; CANCER; IMPACT;
D O I：
10.2217/bmm-2020-0135
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Aim: To determine if neoadjuvant chemoradiotherapy (nCRT) affects p53 and SOX2 expression in esophageal adenocarcinoma (EAC). Materials & methods: Comparison of p53 and SOX2 expression in 100 paired pre- and post-nCRT EAC samples. Results: Aberrant p53 was largely concordant (75/83, 90%), while 13/18 (72%) pre-nCRT samples with wild-type (WT) p53 staining, showed aberrant staining in paired post-nCRT samples. Similarly, 31/45 (69%) with previous WT SOX2 showed SOX2 loss in paired post-nCRT samples, whereas aberrant SOX2 loss was concordant in 50/55 (91%) cases. The prognostic values of both markers regarding survival differ before and after nCRT. Conclusion: Aberrant expression of p53 and SOX2 staining in EAC tissue is unaffected by nCRT. Conversely, the WT-staining pattern frequently changed to aberrant expression.
引用
收藏
页码：785 / 793
页数：9
相关论文
共 50 条
  • [21] Prognostic implication of SOX2 expression in small intestinal adenocarcinoma
    Kim, Jeong Won
    Chung, Joon-Yong
    Ylaya, Kris
    Park, Yoonho
    Jun, Sun-Young
    Hong, Seung-Mo
    Hewitt, Stephen M.
    [J]. VIRCHOWS ARCHIV, 2021, 478 (06) : 1049 - 1060
  • [22] Loss of CD44 and SOX2 Expression is Correlated with a Poor Prognosis in Esophageal Adenocarcinoma Patients
    Honing, Judith
    Pavlov, Kirill V.
    Meijer, Coby
    Smit, Justin K.
    Boersma-van Ek, Wytske
    Karrenbeld, Arend
    Burgerhof, Johannes G. M.
    Kruyt, Frank A. E.
    Plukker, John Th M.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : S657 - S664
  • [23] mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma
    Soslow, RA
    Altorki, NK
    Yang, GY
    Xie, DW
    Yang, CS
    [J]. MODERN PATHOLOGY, 1999, 12 (06) : 580 - 586
  • [24] Prognostic implication of SOX2 expression in small intestinal adenocarcinoma
    Jeong Won Kim
    Joon-Yong Chung
    Kris Ylaya
    Yoonho Park
    Sun-Young Jun
    Seung-Mo Hong
    Stephen M. Hewitt
    [J]. Virchows Archiv, 2021, 478 : 1049 - 1060
  • [25] Loss of CD44 and SOX2 Expression is Correlated with a Poor Prognosis in Esophageal Adenocarcinoma Patients
    Judith Honing
    Kirill V. Pavlov
    Coby Meijer
    Justin K. Smit
    Wytske Boersma-van Ek
    Arend Karrenbeld
    Johannes G. M. Burgerhof
    Frank A. E. Kruyt
    John Th. M. Plukker
    [J]. Annals of Surgical Oncology, 2014, 21 : 657 - 664
  • [26] Gene expression profile of Sox1, Sox2, p53, Bax and Nestin in neural stem cells and adult mouse brain tissues
    Wang, Haifeng
    Wang, Kai
    Guo, Juan
    Wen, Tieqiao
    [J]. BIOCELL, 2019, 43 (02) : 59 - 64
  • [27] p53 mutation expression is not associated with poor prognosis in superficial esophageal adenocarcinoma.
    Ormsby, AH
    Rybicki, LA
    Rice, TW
    Goldblum, JR
    [J]. GASTROENTEROLOGY, 1998, 114 (04) : A659 - A659
  • [28] Mesothelin and p53 expression in pancreatic adenocarcinoma
    Al-Mhsin, Ali Abed
    Radhi, Jasim
    [J]. VIRCHOWS ARCHIV, 2008, 452 : S33 - S33
  • [29] Mesothelin and p53 expression in pancreatic adenocarcinoma
    Abdul-Mhsin, A.
    Radhi, J.
    [J]. PROCEEDINGS OF THE 3RD INTERCONTINENTAL CONGRESS OF PATHOLOGY - FREE PAPERS, 2008, : 57 - 61
  • [30] Profile of p53 gene mutation and abnormal expression of p53 protein in the two types of esophageal cancer.
    Muzeau, F
    Flejou, JF
    Potet, F
    Belghiti, J
    Thomas, G
    Hamelin, R
    [J]. GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 1996, 20 (05): : 430 - 437
12345